Context Therapeutics (NASDAQ:CNTX) Posts Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Context Therapeutics (NASDAQ:CNTX) released its quarterly earnings results on Tuesday. The company reported ($0.08) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.01, FiscalAI reports.

Context Therapeutics Price Performance

Shares of CNTX traded down $0.01 during midday trading on Tuesday, hitting $0.19. 721,502 shares of the company traded hands, compared to its average volume of 1,737,451. The stock has a 50-day moving average of $0.30 and a 200-day moving average of $1.41. Context Therapeutics has a one year low of $0.18 and a one year high of $3.62. The firm has a market cap of $17.18 million, a P/E ratio of -0.39 and a beta of 1.77.

Analyst Upgrades and Downgrades

Several research firms have commented on CNTX. Zacks Research lowered shares of Context Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 12th. Wall Street Zen lowered Context Therapeutics from a “sell” rating to a “strong sell” rating in a report on Monday, July 20th. Weiss Ratings raised Context Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, October 15th. Citigroup reaffirmed an “outperform” rating on shares of Context Therapeutics in a report on Thursday, August 6th. Finally, Lifesci Capital cut Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Context Therapeutics presently has a consensus rating of “Hold” and an average price target of $6.40.

About Context Therapeutics

Context Therapeutics Inc. (NASDAQ:CNTX) is a clinical-stage biotechnology company focused on developing targeted immunotherapies for solid tumors. The company’s approach is centered on T-cell-engaging bispecific antibodies, which are designed to direct the body’s immune cells toward cancer cells expressing specific tumor-associated antigens. Context’s lead program is CTIM-76, an investigational bispecific antibody that targets Claudin 6 (CLDN6) on tumor cells and CD3 on T cells. The program is being developed for patients with CLDN6-positive advanced solid tumors, including ovarian, endometrial, testicular and other cancers.